The silver-lining for PTX is the dollar-value ($1B+) attributable to a platform that achieves a similar objective to OmniCAR and, that is, improved CarT therapy outcome. There's nothing wrong with competition, Dalts, is there... to achieve a desired outcome sooner rather than later?
The fact that Sanofi paid so much for the "masking tech" platform is, in a way, good news for PTX. IMO, it's going to encourage other biotech companies with CarT therapies to seek out ways and means of improving their drugs to compete with the likes of Sanofi. I reckon it's going to put a firecracker up SYC's proverbial even more!
It raises the question too as to what Sanofi intends doing with the newly acquired platform. I doubt that such a company (the 5th biggest pharma co by way of sales) will avail it too cheaply to all and sundry by way of licensing the technology, do you? In fact, Big Pharma are renowned for "shelving" innovative drugs and technologies because they are making so much money in the oncology space by virtue of the fact that cancer has been (supposedly) incurable to date.
As an investor of PTX, I have faith that SYC is on the right path here and the optimisation test results have every chance of catapulting us into the next stage towards collaborations and possible partnerships. PTX100 and 200 have their own value-adding potential as stand-alone therapies as well as potential additions to the in-house OmniCAR platform.
As soon as PTX has advanced OmniCAR to a point where we are are threat in the commercial field, PTX will become a dead set target for a takeover. Big Pharma would hate seeing a "one-stop-shop" like OmniCAR offering to transform every CarT on the market into a cure for cancer!
The above is just Shell's honest opinion (with just a bit of unavoidable bias thrown in for good measure)... fwiw!
